Aarti Drugs Chairman and CEO Prakash Patil retires; Adhish P. Patil promoted to MD

Ceo ResignedCfo ResignedPromoter Family Board EntryKmp ResignedManagement Changes View source PDF Explain this filing

AARTIDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.0%Reaction day

₹432.00

prior close

₹431.05

announcement price

After-mkt

timing

Nifty Microcap 250market-1.3%-1.7% vs market

Pharmaceuticals peers, median of 173sector-0.8%-2.2% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.5

15m

-0.5

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.0-1.3-1.7-0.8-2.2

Next day

-4.1-1.3-2.8-1.2-2.8

-0.8+0.0-0.8-0.4-0.4

-3.3-0.2-3.1-0.1-3.2

-3.2-3.0-0.3-3.0-0.2

-4.5-2.7-1.8-3.1-1.4

-5.2-1.7-3.4-3.0-2.1

15d

-12.0-8.9-3.2-6.9-5.1

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Drugs Chairman, Managing Director and CEO Prakash M. Patil retired early on September 30, 2026, about 8 months before his scheduled term end of May 31, 2027, citing orderly leadership succession. Adhish P. Patil, who was CFO and shares the Patil surname, has been promoted to Managing Director from October 1, 2026. The CFO post is now vacant and a replacement will be appointed later. Changes were approved by shareholders at the AGM on September 26, 2026.

Likely market impact

Promoter family succession at Aarti Drugs. Son takes over as MD while CFO seat is vacant. Watch new CFO appointment and management continuity.